Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.44 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.44 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.41 |
| ▸ | GSK3B | P49841 | 1/20 | 0.41 |
| ▸ | MPO | P05164 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | SPR | P35270 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23778721 | 0.89 | ADORA3 (0.45) | HPGDADORA3ADORA1MEN1KMT2A | |
| SCHEMBL23778733 | 0.88 | THRB (0.45) | HPGDLMNAADORA3TP53 | |
| SCHEMBL23778719 | 0.88 | ADORA1 (0.50) | HPGDLMNAADORA3ADORA2AADORA1 | |
| SCHEMBL23778706 | 0.86 | HPGD (0.43) | HPGDGSK3B | |
| SCHEMBL23778696 | 0.86 | MTNR1A (0.50) | LMNA | |
| SCHEMBL23778678 | 0.85 | HPGD (0.40) | HPGDTP53 | |
| SCHEMBL23778716 | 0.84 | MTNR1A (0.45) | HPGDADORA3ADORA2AADORA1GSK3B | |
| SCHEMBL24088855 | 0.83 | LMNA (0.51) | HPGDLMNATP53 | |
| SCHEMBL23778657 | 0.83 | MTNR1A (0.46) | LMNAADORA3ADORA2AADORA1TP53 | |
| SCHEMBL23778705 | 0.81 | GSK3B (0.41) | HPGDGSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12378203-B2 | Imidazole compounds, process for the synthesis and uses thereof | AHAMMUNE BIOSCIENCES PRIVATE LIMITED (IN) | 2025-08-05 | — | — | US | claimed |
| EP-3873890-A1 | NOVEL IMIDAZOLE COMPOUNDS, PROCESS FOR THE SYNTHESIS AND USES THEREOF | Ahammune Biosciences Private Limited (IN) | 2021-09-08 | — | — | EP | claimed |
| US-20260001850-A1 | NOVEL IMIDAZOLE COMPOUNDS, PROCESS FOR THE SYNTHESIS AND USES THEREOF | AHAMMUNE BIOSCIENCES PRIVATE LTD (IN) | 2026-01-01 | — | — | US | disclosed |
| US-12378203-B2 | Imidazole compounds, process for the synthesis and uses thereof | AHAMMUNE BIOSCIENCES PRIVATE LIMITED (IN) | 2025-08-05 | — | — | US | disclosed |
| US-20210380538-A1 | NOVEL IMIDAZOLE COMPOUNDS, PROCESS FOR THE SYNTHESIS AND USES THEREOF | AHAMMUNE BIOSCIENCES PRIVATE LTD (IN) | 2021-12-09 | — | — | US | disclosed |
| EP-3873890-A1 | NOVEL IMIDAZOLE COMPOUNDS, PROCESS FOR THE SYNTHESIS AND USES THEREOF | Ahammune Biosciences Private Limited (IN) | 2021-09-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210380538-A1 | NOVEL IMIDAZOLE COMPOUNDS, PROCESS FOR THE SYNTHESIS AND USES THEREOF | IDO1, IDO2, NFATC1 | HPGD 258/4885LMNA 4399/4885ADORA3 3181/4885 |
| US-20260001850-A1 | NOVEL IMIDAZOLE COMPOUNDS, PROCESS FOR THE SYNTHESIS AND USES THEREOF | MALT1, ADRM1, CYP11B1 | HPGD 2454/4885LMNA 2193/4885ADORA3 747/4885 |
| US-12378203-B2 | Imidazole compounds, process for the synthesis and uses thereof | IDO1, IDO2, NFATC1 | HPGD 190/4885LMNA 4397/4885ADORA3 3044/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.